Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment
| Autor: | K. Rajender Reddy, Greg Hooper, G. Teuber, Antonio Craxì, Diethelm Messinger, Adrian M. Di Bisceglie, Patrick Marcellin, Donald M. Jensen, Carlos E. Brandao-Mello, Fernando Tatsch, Cynthia Wat, Antonio Olveira Martin, B. Freilich, Pietro Andreone |
|---|---|
| Přispěvatelé: | Marcellin, P, Craxi, A, Brandao-Mello, CE, Di Bisceglie, AM, Andreone, P, Freilich, B, Rajender Reddy, K, Olveira Martín, A, Teuber, G, Messinger, D, Hooper, G, Wat, C, Tatsch, F, Jensen, DM, Patrick Marcellin, Antonio Craxi, Carlos E. Brandao-Mello, Adrian M. Di Bisceglie, Pietro Andreone, Bradley Freilich, K. Rajender Reddy, Antonio Olveira Martín, Gerlinde Teuber, Diethelm Messinger, Greg Hooper, Cynthia Wat, Fernando Tatsch, Donald M. Jensen |
| Rok vydání: | 2013 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Interferon alpha-2 Antiviral therapy Antiviral Agents Gastroenterology Polyethylene Glycols law.invention chemistry.chemical_compound Pharmacotherapy Randomized controlled trial nonresponder Predictive Value of Tests law Internal medicine Ribavirin chronic hepatitis C Humans Medicine peginterferon Adverse effect Randomized Controlled Trials as Topic business.industry Interferon-alpha virus diseases Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease retreatment sustained virological response Recombinant Proteins digestive system diseases Regimen Treatment Outcome chemistry Predictive value of tests Relative risk Retreatment Drug Therapy Combination Female business |
| Zdroj: | Journal of Clinical Gastroenterology. 47:786-793 |
| ISSN: | 0192-0790 |
| Popis: | GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa). BACKGROUND: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|